We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review.
- Authors
Linda Nguyen; Marshalek, Patrick J.; Weaver, Cory B.; Cramer, Kathy J.; Pollard, Scott E.; Matsumoto, Rae R.
- Abstract
Objective: This study evaluated the effectiveness and safety of subanesthetic doses of ketamine using an off-label, transmucosal administration route in patients with treatment-resistant depression. Methods: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant major depressive disorder. Seventeen such patients who received subanesthetic doses of ketamine were included. Patient demographics, efficacy (drug refill, clinician notes), side effects, and concurrent medications were assessed. Results: Benefit from low-dose transmucosal ketamine was noted in 76% of subjects (average age 48 years, 88% female), with a dose duration lasting 7-14 days. No notable side effects were noted. The most common classes of concurrent medications to which ketamine was added were serotonin-norepinephrine reuptake inhibitors (59%), stimulants (47%), folate replacement (47%), and benzodiazepines (47%). Conclusion: Our results provide preliminary evidence of the effectiveness and safety of lowdose transmucosal ketamine in treatment-resistant patients. A controlled, prospective pilot study is warranted to validate these findings.
- Subjects
KETAMINE abuse; ANESTHESIA adjuvants; ANESTHETICS; ELECTRODIAGNOSIS; ELECTROENCEPHALOGRAPHY; NEUROBEHAVIORAL disorders; NEUROPSYCHIATRY
- Publication
Neuropsychiatric Disease & Treatment, 2015, Vol 11, p2667
- ISSN
1176-6328
- Publication type
Article
- DOI
10.2147/NDT.S88569